Advancing risk stratification for DSP cardiomyopathy with postmortem genetic testing

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Both DSP cardiomyopathy and plakophilin 2 are associated with arrhythmogenic right ventricular cardiomyopathies via a desmosomal mechanism.

However, the diagnostic and risk stratification criteria for plakophilin 2-associated cardiomyopathy are less accurate for DSP cardiomyopathy. In the era of genetic-based personalized medicine, gene-centric strategies are crucial for postmortem analysis and accurate risk assessment. Postmortem genetic testing is an efficient and rapid method to investigate potential disease-causing mechanisms.

WES, a powerful tool for post-mortem genetic testing, provides an effective and rapid strategy for studying potential pathogenic mechanisms. In this study, we examined a proband with sporadic cardiomyopathy and SCD. The proband had myocarditis. Combining WES with cardiomyopathy-related gene filtering identified a novel deletion variant (NM_004415.3: c.3930_3933del:p.K1310Nfs*38) in DSP.

Source:
Journal reference:

Wang, C., et al. (2024). Identification of a Novel DSP Variant in a Patient with Sudden Cardiac Death through Post-Mortem Genetic Investigation. Cardiovascular Innovations and Applications. doi.org/10.15212/cvia.2024.0043.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mapping Lyme bacteria for better patient care